Skip to main content
IMRX
NASDAQ Life Sciences

Immuneering Reports Strong Phase 2a Pancreatic Cancer Data, Confirms Phase 3 Launch

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$4.5
Mkt Cap
$290.814M
52W Low
$1.63
52W High
$10.08
52W Position info
176% above low
Off High info
55% below high
Rel. Volume info
7.0× avg
Market data snapshot near publication time

IMRX has more than doubled off its 52-week low of $1.63 on elevated volume (7.0× avg).

Summary

Immuneering announced updated Phase 2a clinical data for its lead pancreatic cancer drug, atebimetinib, demonstrating significantly improved survival rates and a favorable safety profile, alongside confirming the launch of its pivotal Phase 3 trial.


Key Events · Product Development and Regulatory · IMRX

  • Updated Phase 2a Clinical Data

    Atebimetinib showed a median overall survival (mOS) of 17.3 months in first-line pancreatic cancer patients, significantly exceeding the 8.5 months reported for standard of care.

  • Favorable Safety Profile

    The drug combination was generally well tolerated, with no new safety signals and manageable Grade ≥ 3 adverse events, including Anemia (16%) and Neutropenia (18%).

  • Pivotal Phase 3 Trial Confirmed

    The company confirmed the launch of its registrational Phase 3 MAPKeeper-301 trial for atebimetinib in pancreatic cancer, with topline data expected in mid-2028.

  • Pipeline Milestones Outlined

    Additional upcoming milestones include a clinical trial in non-small cell lung cancer in H2 2026 and IND-enabling studies for a new candidate in mid-2027.


Analysis · IMRX · Life Sciences

Immuneering has formally disclosed updated, highly positive Phase 2a clinical trial data for atebimetinib in first-line pancreatic cancer, showing a median overall survival of 17.3 months, nearly double the standard of care. This 8-K also confirms the launch of the pivotal Phase 3 trial and outlines key pipeline milestones, providing a comprehensive update on the company's lead program.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IMRX was trading at $4.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $290.8M. The 52-week trading range was $1.63 to $10.08. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMRX - Latest Insights

IMRX
Oct 29, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.02
Real-time Price: $3.71 info
Change: -$0.310 (-8%) info
Market Cap: $240.271M info
IMRX
Oct 29, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.02
Real-time Price: $3.71 info
Change: -$0.310 (-8%) info
Market Cap: $240.271M info
IMRX
Sep 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.36
Real-time Price: $3.71 info
Change: -$0.650 (-15%) info
Market Cap: $240.271M info
IMRX
Aug 05, 2026, 7:41 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.23
Real-time Price: $3.71 info
Change: -$0.520 (-12%) info
Market Cap: $240.271M info
IMRX
Jul 21, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.51
Real-time Price: $3.71 info
Change: -$0.800 (-18%) info
Market Cap: $240.271M info